Germany's Merck to buy Bio-Techne for $73 per share - Finance news and analysis from Global Banking & Finance Review
Finance

Germany's Merck to buy Bio-Techne for $73 per share

Published by Global Banking & Finance Review

Posted on June 25, 2026

2 min read

· Last updated: June 25, 2026

Add as preferred source on Google

Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal

Merck's Strategic Acquisition of Bio-Techne

Deal Overview and Market Impact

June 25 (Reuters) - German drugmaker Merck KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne Corp for $11.3 billion, expanding its presence in the life sciences market.

Shares of Bio-Techne rose 22% in premarket trading following Merck's offer of $73 per share, which implies a 24% premium to Bio-Techne's close on Wednesday.

Access to Bio-Techne's Expertise and Products

With this deal, Merck will gain access to Bio-Techne's expertise and supplies of research reagents, proteins, antibodies, analytical instruments and other tools that are used by scientists and drug developers.

Context: Recent Healthcare Mergers and Acquisitions

The deal follows a series of large healthcare transactions this year, including Danaher's $9.9 billion acquisition of patient-monitoring company Masimo in February, as medical technology and life sciences firms seek to broaden their product offerings and gain market share across multiple segments.

Significance and Financial Details

Merck's Largest Life Sciences Deal Since Sigma-Aldrich

The Bio-Techne acquisition is Merck's largest life sciences deal since its $17 billion takeover of Sigma-Aldrich in 2014, which bolstered the German group's laboratory supplies and research tools business and accelerated its diversification beyond pharmaceuticals.

Funding and Financial Strategy

Cash and Debt Financing

The German firm said it would fund the Bio-Techne acquisition through a combination of cash and debt. The company has cash and cash equivalents of about 2.74 billion euros, according to its latest quarterly results.

Expected Timeline and Cost Savings

The deal is expected to close by late 2026 or early 2027. Merck expects cost savings of about 140 million euros to be fully realized by the third year after the deal is closed.

(Reporting by Danny Callaghan, Christy Santhosh and Padmanabhan Ananthan; Editing by Linda Pasquini and Shinjini Ganguli)

Key Takeaways

  • The all‑cash $73 per share offer by Merck KGaA implies an enterprise value of approximately $11.3 billion and reflects a ~36% premium over Bio‑Techne’s one‑month VWAP, signaling a confident valuation of its life‑science assets. (reddit.com)
  • The acquisition would enhance Merck’s life‑science portfolio and follows a recent trend of significant biotech M&A by Merck KGaA, including prior purchases like SpringWorks (~$3.9 billion) and Verona Pharma (~$10 billion), underscoring its active expansion strategy. (streetinsider.com)
  • Bio‑Techne, a U.S. life‑sciences reagents and instrument maker with ~$1.2 billion in annual sales but volatile earnings, stands to gain immediate value from the deal; Merck may benefit from its strong R&D pipeline and complementary offerings. (sec.gov)

References

Frequently Asked Questions

What is Merck KGaA acquiring Bio-Techne for?
Merck KGaA has agreed to acquire Bio-Techne Corp for $73 per share in cash, valuing the deal at about $11.3 billion.
What premium is offered in Merck's Bio-Techne bid?
The $73 per share offer represents a 36% premium over Bio-Techne’s one-month volume weighted average share price.
How will Merck fund the purchase of Bio-Techne?
Merck will pay $73 per share in cash to acquire Bio-Techne.
Who reported on the Merck and Bio-Techne acquisition?
The deal was reported by Danny Callaghan and edited by Linda Pasquini.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category